Forschungsprojekte
Ergebnisse pro Seite:
10
2005 - 2006
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Glivec (Imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematological malignancies.- Univ.-Prof. Dr. Thomas